In this task, you are given a summary for US Congressional and California state bill, your task is to generate a Title for this bill. The preferred titles are under forty words and mention the purpose of the bill.

Ex Input:
End Abuse in Later Life Act of 2011 - Amends the Violence Against Women Act of 1994 to authorize appropriations for and revise provisions governing the grant program to end abuse of individuals age 50 and over that is authorized to be conducted by the Attorney General through the Director of the Office of Violence Against Women.

Makes currently listed activities mandatory for grant recipients and sets forth as additional permissible activities: (1) providing training programs to assist attorneys, health care providers, faith-based leaders, or other community-based organizations in recognizing and addressing instances of such abuse; and (2) conducting outreach activities and public awareness campaigns to ensure that abuse victims receive appropriate assistance.

Includes as eligible entities: (1) a population-specific organization with demonstrated experience in assisting individuals over 50 years of age; (2) a victim service provider with demonstrated experience in addressing domestic violence, dating violence, sexual assault, and stalking; or (3) a state, tribal, or territorial domestic violence or sexual assault coalition. Requires each eligible entity to demonstrate that it is a part of a multidisciplinary partnership that includes a law enforcement agency, a prosecutor's office, a victim service provider, and a nonprofit program or government agency with demonstrated experience in assisting individuals in later life.

Directs the Attorney General to: (1) give priority to proposals providing population-specific services to racial and ethnic minorities and other underserved populations; and (2) conduct research to promote understanding of, prevention of, and response to abuse in later life.

Amends the Violence Against Women Act of 1994 to replace the term "elder law" with "abuse in later life."

Ex Output:
A bill to establish a grant program to enhance training and services to prevent abuse in later life.


Ex Input:
Amends the Federal Food, Drug, and Cosmetic Act to require license applications for new drugs and biological products to assess such drug's or product's safety and effectiveness for relevant pediatric subpopulations, including dosage.Permits extrapolation from adult studies where the course of the disease and the effects of the drug are sufficiently similar in all populations.Permits deferral of such assessments if adult studies are completed earlier and the applicant submits a plan for or a description of planned or ongoing pediatric studies.Permits full waiver of such assessments if: (1) studies are highly impractical or impossible; (2) the evidence strongly suggests that the drug or product would be ineffective or unsafe in all pediatric age groups; (3) there is no meaningful therapeutic advantage or benefit in the pediatric population; or (4) the drug or product is not likely to be used in a substantial number of pediatric patients.Permits partial waivers at the request of an applicant for a specific pediatric subpopulation if any of the full waiver grounds apply to that subpopulation or reasonable attempts for a pediatric formulation for that subpopulation have failed.Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.Authorizes the Secretary of Health and Human Services to specify a date for submission of pediatric assessments if: (1) the drug or biological product would represent a meaningful therapeutic benefit for pediatric patients for one or more claimed indications and the absence of adequate labeling could pose significant risks to pediatric patients; or (2) it is used for a number of pediatric patients for the labeled indications and the absence of adequate labeling could pose significant risks to pediatric patients. Sets forth criteria for full waiver and partial waivers of such requirement. Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.Requires the Secretary to issue a written request for related pediatric studies under the Public Health Service Act before requiring an assessment for a drug.States that drugs or products with delayed assessments may be deemed misbranded and subject to seizure and injunctive proceedings, though not penalties.

Ex Output:
To amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients.


Ex Input:
Health Care Price Transparency Promotion Act of 2016 This&nbsp;bill amends title XIX (Medicaid) of the Social Security Act to require state Medicaid plans to provide that the state will establish and maintain laws to: (1)&nbsp;require disclosure of information on hospital charges, (2) make such information available to the public, and (3)&nbsp;provide individuals with information about estimated out-of-pocket costs for health care services. 

Ex Output:

Health Care Price Transparency Promotion Act of 2016